PALI — PALISADE BIO, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 1357459 ·
Last close
$1.01
Market Cap
$181.07M
52W High
$2.86
52W Low
$0.99
ADV30
3,204,747
Next earnings
—
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -15,700,000 -14,623,000 118,545,000 113,613,000 6,105,000
Jun 2026 500,000 — -11,698,000 -10,574,000 127,315,000 125,172,000 5,567,000
Mar 2026 0 — -10,748,000 -9,600,000 133,315,000 132,628,000 5,953,000
Dec 2025 0 — -9,981,000 -8,899,000 134,344,000 133,385,000 4,964,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-26,396,000
Investing CF
—
Financing CF
$134,811,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.55
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-187,522,000
Inventory
—
Receivables
$3,000
ST Investments
—
EBIT TTM
$-43,693,000
Pretax Income TTM
$-43,696,000
Interest Exp TTM
$3,000
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$500,000
EBITDA
$-48,124,752
Free Cash Flow
$-11,907,250
Enterprise Value
$87,180,160
Total Cash
$113,613,000
Total Debt
$0
Shares Out
179,277,820
Trailing EPS
$0.92
Book Value
$0.65
ROE
-75.6%
ROA
-47.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -18,056,000 -16,781,000 134,344,000 4,964,000 129,380,000 -10,847,000
Dec 2024 0 -14,859,000 -14,438,000 10,880,000 3,388,000 7,492,000 -12,193,000
Dec 2023 250,000 -12,845,000 -12,300,000 14,052,000 2,739,000 11,313,000 -11,133,000
Dec 2022 0 -15,311,000 -14,260,000 15,763,000 3,284,000 12,479,000 -13,360,000

TTM Snapshot

Revenues TTM
$500,000
NetIncome TTM
$-31,941,000
OpCashFlow TTM
—
Assets (Latest)
$127,315,000
Forward EPS
$-0.33

Peers — same industry

TickerNameMarket CapLastDaily %
ACOG Alpha Cognition Inc. $174.57M $7.92 —
ARTV Artiva Biotherapeutics, Inc. $190.81M $3.86 —
CGEN COMPUGEN LTD $191.34M $2.02 —
IKT Inhibikase Therapeutics, Inc. $193.57M $1.38 —
IPHYF Innate Pharma SA $168.56M $1.51 —

News headlines (Yahoo Finance, 1h cache)

Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs
2026-11-10 21:25 · Yahoo
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
2026-10-28 12:32 · Yahoo
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
2026-10-20 12:05 · Yahoo
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
2026-10-12 12:05 · Yahoo
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
2026-09-28 12:50 · Yahoo
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s
2026-09-27 17:01 · Yahoo
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
2026-09-22 12:35 · Yahoo
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-21 13:00 · Yahoo
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
2026-07-27 11:30 · Yahoo
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?
2026-06-29 17:49 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.